【26】The third and largest trial, the Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP), conducted in the United Kingdom, compared prostate cancer mortality among men whose primary care practices were ran...
“These men would not likely importantly benefit from further testing,” he toldHemOnc Today. “They could be spared from further testing. For about half the population, you could eliminate further intervention on these men who have very little if anything to gain from screening. ...
The results of thelong-term screening study, the EuropeanRandomised Study of Screening forProstate Cancer (ERSPC), have clearlydemonstrated a decrease in prostate-cancer-specific mortality and metastaticdisease in men aged 50–69 yearsundergoing regular PSA testing, withnumbers needed to screen and ...
Bell K and Kazanjian A (2011) PSA testing: molecular technologies and men's experience of prostate cancer survivorship. Health, Risk & Society 13(2): 183-196.Bell K., Kazanjian A. PSA testing: Molecular technologies and men's experience of prostate cancer survivorship. Health, Risk & ...
Of these 129 men, 42 had not undergone PSA testing at all, 15 eligible men had not received a prostate biopsy, 68 had a PSA level of less than 3.0 ng/mL at screening (and therefore were below the threshold for recommending biopsy), and 4 had a benign prostate biopsy result (eTable ...
meninBACKGROUND: Limits on the frequency of PSA testing and an endpoint for the age of the screened population have not been established. The numbers of performed serum PSA tests, cost evolution, and utilization patterns by various subspecialties in one medical center were analyzed to gain ...
PSA testing detects prostate cancer at an earlier stage. .. The benefit of PSA is unproven as a population based screening test. - Men should be advised of the availability and reliability of PSA testing, and the potential risks and benefits of treatment - If proceeding with testing, then bo...
Frequent testing for PSA may find prostate cancers earlier in their natural history, but the anatomical distribution of these cancers appears to be comparable to those identified in the United Kingdom. In summary, our analysis suggests that the majority of men presenting with prostate cancer ...
Methods: Seven hundred and eighty-five general practitioner (GP) practices in England and Wales were randomised to a population-based PSA testing or standard care and then approached for consent to participate. In the intervention arm, men aged 50–69 years were invited to undergo PSA testing, ...
Eliminating the PSA test to screen for prostate cancer would be taking a big step backwards and would likely result in rising numbers of men with metastatic cancer at the time of diagnosis, predicted a University of Rochester Medical Center analysis published in the journal,Cancer. ...